Here are four points:
1. Patients with chronic pain in their lower limbs from complex regional pain syndrome may benefit from this therapy.
2. St. Jude Medical believes physicians can gain access to the DRG stimulation in the next few months.
3. The FDA approved the therapy in part because of the ACCURATE IDE study results, which tested DRG stimulation via the Axium Neurostimulator System on patients with neuropathic chronic pain.
4. The Axium system received a CE Mark in November 2011.
More articles on devices:
How will Stryker’s acquisitions impact the company? 5 key notes
Stryker buys Physio-Control for $1.28B in 3rd February 2016 acquisition: 6 key notes
Medtech sells ROSA system in France: 3 things to know
